Acellbia vs Rituximab-abbs (Truxima)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline
Acellbia
Marketed by Biocad
NCT02744196 · Phase 3 · completed
This was a randomized, triple-blinded, placebo-controlled trial with 159 patients and a validated disease-response primary endpoint (ACR20). The result was clearly positive: 65.7% of Acellbia-treated patients achieved ACR20 at week 24 versus 29.4% on placebo (p<0.0001).
Reported efficacy
Percentage of patients who developed ACR20 response on 24 week of therapy (Week 24): ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%) (met)
Result source: NCT02744196
Rituximab-abbs (Truxima)
Marketed by Celltrion and partners
NCT02149121 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with an adequately sized population (384 enrolled) that pre-specified formal equivalence margins for both its pharmacokinetic and its clinical disease-activity (DAS28-CRP) primary endpoints, and every comparison landed entirely within the required margin, meaning the biosimilar demonstrated therapeutic equivalence to the reference product on a validated hard clinical measure of rheumatoid arthritis activity, not just a proxy lab value.
Reported efficacy
Analysis of Serum AUC0-last of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA); Analysis of Serum AUC0-inf of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Serum Cmax of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Change From Baseline of DAS28 (CRP) at Week 24 (ANCOVA) (at Week 24 of the Main Study Period): Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%). (met)
Result source: NCT02149121
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Acellbia | Rituximab-abbs (Truxima) |
|---|---|---|
| ACR20 | 65.7% vs 29.4%a+36.3 vs placeboNCT02744196 | —Not reported |
| ACR50 | —Not posted · NCT02744196 | —Not reported |
| ACR70 | —Not posted · NCT02744196 | —Not reported |
| DAS28-CRP remission | —Not posted · NCT02744196 | —Not reported |
| HAQ-DI, change | —Not posted · NCT02744196 | —Not reported |
| Modified Sharp score, change | —Not posted · NCT02744196 | —Not reported |
ACR20
- Acellbia
- 65.7% vs 29.4%a+36.3 vs placeboNCT02744196
- Rituximab-abbs (Truxima)
- —Not reported
ACR50
- Acellbia
- —Not posted · NCT02744196
- Rituximab-abbs (Truxima)
- —Not reported
ACR70
- Acellbia
- —Not posted · NCT02744196
- Rituximab-abbs (Truxima)
- —Not reported
DAS28-CRP remission
- Acellbia
- —Not posted · NCT02744196
- Rituximab-abbs (Truxima)
- —Not reported
HAQ-DI, change
- Acellbia
- —Not posted · NCT02744196
- Rituximab-abbs (Truxima)
- —Not reported
Modified Sharp score, change
- Acellbia
- —Not posted · NCT02744196
- Rituximab-abbs (Truxima)
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Acellbia: 0 of 4 rows · Rituximab-abbs (Truxima): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Acellbia | Rituximab-abbs (Truxima) |
|---|---|---|
| Dropout rate | — | 13%CT-P10 (Main Study Period) NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more result—CT-P10/CT-P10 (Extension Study Per NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Discontinued due to AEs | — | 1.2%CT-P10 (Main Study Period) NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more result—CT-P10/CT-P10 (Extension Study Per NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Serious AEs | — | 8.1%CT-P10 (Main Study Period) NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more result3.3%CT-P10/CT-P10 (Extension Study Per NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Most frequent reported AEs | — | infusion-related reaction 20.5% upper respiratory tract infection 14.9% urinary tract infection 9.3% NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more resultupper respiratory tract infection 8.2% urinary tract infection 6.6% infusion-related reaction 3.3% NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Acellbia
Rituximab-abbs (Truxima)
show 3 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acellbia's landscape · Rituximab-abbs (Truxima)'s landscape